Rosenberg L, Rao R S, Palmer J R, Strom B L, Stolley P D, Zauber A G, Warshauer M E, Shapiro S
Slone Epidemiology Unit, School of Public Health, Boston University School of Medicine, Brookline, Mass 02146, USA.
JAMA. 1998 Apr 1;279(13):1000-4. doi: 10.1001/jama.279.13.1000.
Recent epidemiologic studies have raised the concern that calcium channel blocker use may increase the risk of cancer overall and of several specific cancers.
To assess whether calcium channel blocker use increases the risk of cancer overall and of specific cancers.
Case-control drug surveillance study based on data collected from 1983 to 1996.
Hospitals in Baltimore, Md, New York, NY, and Philadelphia, Pa.
A total of 9513 patients aged 40 to 69 years with incident cancer of various sites and 6492 controls aged 40 to 69 years admitted for nonmalignant conditions.
Incident cancer overall and 23 specific cancers.
Calcium channel blocker use was unrelated to the risk of cancer overall (relative risk [RR], 1.1; 95% confidence interval [CI], 0.9-1.3). Use was not significantly associated with increased risks of individual cancers, including those previously implicated, except cancer of the kidney (RR, 1.8; 95% CI, 1.1 -2.7). Recent use, use for 5 or more years, and use of individual calcium channel blocker drugs were also not associated with cancer incidence. Use of beta-blockers and angiotensin-converting enzyme inhibitors was generally unrelated to cancer overall or individual cancers, but both were associated with kidney cancer (RR, 1.8; 95% CI, 1.3-2.5; and RR, 1.9; 95% CI, 1.2-3.0, respectively).
The present study suggests that the use of calcium channel blockers is unrelated to an increase in the overall risk of cancer or of individual cancers, except kidney cancer, which has been associated with hypertension or drugs to treat hypertension in previous studies.
近期的流行病学研究引发了人们对使用钙通道阻滞剂可能增加总体癌症风险以及几种特定癌症风险的担忧。
评估使用钙通道阻滞剂是否会增加总体癌症风险以及特定癌症的风险。
基于1983年至1996年收集的数据进行的病例对照药物监测研究。
马里兰州巴尔的摩、纽约市和宾夕法尼亚州费城的医院。
共有9513名年龄在40至69岁之间的新发各部位癌症患者以及6492名年龄在40至69岁之间因非恶性疾病入院的对照者。
总体新发癌症以及23种特定癌症。
使用钙通道阻滞剂与总体癌症风险无关（相对风险[RR]，1.1；95%置信区间[CI]，0.9 - 1.3）。除肾癌外，使用钙通道阻滞剂与个体癌症风险增加无显著关联，包括那些先前被认为有关联的癌症（RR，1.8；95% CI，1.1 - 2.7）。近期使用、使用5年或更长时间以及使用个体钙通道阻滞剂药物也与癌症发病率无关。使用β受体阻滞剂和血管紧张素转换酶抑制剂通常与总体癌症或个体癌症无关，但两者均与肾癌有关（RR分别为1.8；95% CI，1.3 - 2.5；以及RR，1.9；95% CI，1.2 - 3.0）。
本研究表明，使用钙通道阻滞剂与总体癌症风险或个体癌症风险增加无关，但肾癌除外，在先前的研究中肾癌已与高血压或治疗高血压的药物相关联。
